<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The JAK2(V617F) mutation does not elucidate the <z:hpo ids='HP_0003812'>phenotypic variability</z:hpo> observed in myeloproliferative <z:hpo ids='HP_0002664'>neoplasm</z:hpo> (MPN) families </plain></SENT>
<SENT sid="1" pm="."><plain>A putative <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene, TET2, was recently implicated in MPN and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> through the identification of acquired mutations affecting hematopoietic stem cells </plain></SENT>
<SENT sid="2" pm="."><plain>The present study analyzed the TET2 gene in 61 MPN cases from 42 families </plain></SENT>
<SENT sid="3" pm="."><plain>Fifteen distinct mutations were identified in 12 (20%) JAK2(V617F)-positive or -negative patients </plain></SENT>
<SENT sid="4" pm="."><plain>In a patient with 2 TET2 mutations, the analysis of 5 blood samples at different phases of <z:e sem="disease" ids="C0017925" disease_type="Disease or Syndrome" abbrv="">her disease</z:e> showed the sequential occurrence of JAK2(V617F) and TET2 mutations concomitantly to the disease evolution </plain></SENT>
<SENT sid="5" pm="."><plain>Analysis of familial segregation confirmed that TET2 mutations were not inherited but somatically acquired </plain></SENT>
<SENT sid="6" pm="."><plain>TET2 mutations were mainly observed (10 of 12) in patients with primary <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> or patients with <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera or <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e> who secondarily evolved toward <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> </plain></SENT>
</text></document>